Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

Primary Objective

This Expanded Access (EAP) Protocol pertains to the provision of treatment by use of an investigational product. Such access may be considered for patients with serious/life-threatening diseases or conditions, where there are no alternative treatments or where alternative treatments have been exhausted. Cilta-cel OOS does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.

Is This Study For You?

Let's Get Started!




University of Colorado Hospital

Principal Investigator
Photograph of Jonathan Gutman

Jonathan Gutman

Study ID

Protocol Number: 23-0111

More information available at NCT05346835


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers